GAMMA Investing’s Monopar Therapeutics MNPR Stock Holding History

GAMMA Investing’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.11K	Buy	39 +14	+56%	+$1.5K	﹤0.01%	3823
2026 Q2	$2.32K	Sell	25 -4	-14%	-$248	﹤0.01%	3700
2026 Q1	$1.59K	Buy	29 +15	+107%	+$906	﹤0.01%	3732
2025 Q4	$914	Buy	14 +3	+27%	+$245	﹤0.01%	3813
2025 Q3	$898	Buy	+11	New	+$492	﹤0.01%	3633

Other funds holding MNPR

Gerber LLC Columbus, Ohio $220M AUM 16.73% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

GAMMA Investing's MNPR Position: Q3 2026 in Review

GAMMA Investing increased its Monopar Therapeutics (MNPR) stake by 56% in Q3 2026, buying an estimated $1.5K and bringing the position to 39 shares worth $3.11K. The position accounts for ﹤0.01% of the portfolio, ranked #3823.

GAMMA Investing first reported a position in MNPR in Q3 2025 and has held it in 5 quarters since. 5 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

GAMMA Investing held 39 shares of Monopar Therapeutics worth $3.11K as of Q3 2026.
GAMMA Investing bought 14 Monopar Therapeutics shares in Q3 2026, an estimated $1.5K.
Monopar Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3823 holding.
GAMMA Investing first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 5 quarters since.
5 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.